Full-Time

Senior Sales Operations Manager

Updated on 3/14/2025

PROCEPT BioRobotics

PROCEPT BioRobotics

501-1,000 employees

Develops robotic solutions for BPH treatment

Compensation Overview

$144k - $170kAnnually

+ Annual Bonus + Equity/RSUs

Senior, Expert

No H1B Sponsorship

San Jose, CA, USA

This is a hybrid position, which implies that the candidate will be required to work in the office for part of the week.

Category
Sales Development Representative
Sales & Account Management
Required Skills
Salesforce
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor's degree in business administration, finance, or a related field. MBA or equivalent preferred.
  • 5+ years of proven experience in sales operations required
  • 8+ years of related experience required
  • Strong understanding of sales processes and sales technologies.
  • Proficiency in data analysis, reporting tools (Excel) and CRM software (Salesforce).
  • Experience with sales forecasting, pipeline management, incentive compensation planning, quota setting and territory design.
Responsibilities
  • Maintain commercial team roster and team assignments to enable seamless onboarding and team transitions.
  • Define and maintain territory assignments to ensure appropriate alignment to meet business needs across commercial teams.
  • Lead the sales role capacity planning and modeling to optimize revenue and efficiency.
  • Design, develop and write global incentive compensation plans to align with performance-based compensation philosophy.
  • Model quota and compensation to facilitate incentive strategy and administration.
  • Partner with commercial leadership and finance to manage compensation programs, including quota setting, commissions calculations and administration of incentive compensation platform (Performio).
  • Maintain global commercial price book and collaborate with marketing to deploy changes, ensuring consistency of pricing, discount structures, and systems.
  • Conduct deal analysis and prepare models for Commercial Contracts to drive strategic decisions and address customer needs.
  • Analyze and report on key sales KPIs such as revenue by channel, win/loss rates, quota attainment, pipeline velocity, and forecast accuracy.
  • Support ad hoc sales analysis as required by Commercial team.
  • Oversee the implementation and improvement of sales technologies to ensure they support the team’s needs and performance.
Desired Qualifications
  • Experience with Salesforce CRM and BI tools such as Tableau.
  • Familiarity with commissions platforms, ideally Performio.
  • Analytical mindset with the ability to interpret data and make actionable recommendations.
  • Ability to work in a fast-paced, dynamic environment and adapt to changing priorities.
  • Excellent communication skills with the ability to collaborate effectively across cross-functional teams from sales reps to C-level.
  • Strong project management skills with the ability to manage multiple tasks and deadlines.
  • Detail-oriented with a focus on accuracy and quality.
  • Experience in medical device or healthcare life sciences industry.

PROCEPT BioRobotics develops robotic solutions specifically for treating benign prostatic hyperplasia (BPH), a condition that affects many older men by causing prostate enlargement and urinary issues. Their main product, the AquaBeam Robotic System, utilizes Aquablation therapy, which combines real-time imaging, robotics, and waterjet technology to precisely remove prostate tissue in a minimally invasive manner. This system is designed for urologists and healthcare facilities, and the company generates revenue through the sale of the AquaBeam system and its disposable components, as well as offering training and support services. PROCEPT BioRobotics stands out from competitors by providing a solution that ensures predictable outcomes and minimizes complications, ultimately enhancing patient quality of life. The company's goal is to improve surgical procedures and patient outcomes in the treatment of BPH.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2009

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval for Aquablation therapy in prostate cancer suggests expansion opportunities.
  • Significant investment in robotics highlights a robust funding environment for PROCEPT.
  • Long-term data confirms Aquablation therapy's efficacy, driving further clinical adoption.

What critics are saying

  • HYDROS™ Robotic System poses a competitive threat with advanced features.
  • Established companies like Intuitive Surgical challenge PROCEPT's market position.
  • Continuous R&D investment is needed to maintain technological leadership.

What makes PROCEPT BioRobotics unique

  • AquaBeam Robotic System offers minimally invasive BPH treatment with high precision.
  • Aquablation therapy provides effective outcomes regardless of prostate size or surgeon experience.
  • Over 100 peer-reviewed publications support the clinical advantages of Aquablation therapy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Parental Leave

Paid Holidays

Wellness Program

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

3%
Stock Titan
Mar 14th, 2025
PROCEPT BioRobotics(R) Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada

SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) - PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time.

Hit Consultant
Jan 27th, 2025
Mount Sinai Performs Nyc’S First Enlarged Prostate Procedure With Hydros™ Robotic System

What You Should Know:– The Mount Sinai Hospital has achieved a significant milestone in men’s health by performing New York City’s first procedures using the HYDROS™ Robotic System.– The technology offers a minimally invasive treatment option for benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate.Impact of BPHBPH is a prevalent condition affecting millions of men, particularly those over 60. While non-cancerous, BPH can significantly impact quality of life, causing urinary symptoms such as frequent urination, weak stream, and nighttime urgency.Minimally Invasive Procedure Offers Hope for Men with BPHThe HYDROS™ system represents a major advancement in BPH treatment, building upon traditional methods like transurethral resection of the prostate (TURP) and laser treatments. It offers several key innovations:AI-Powered Treatment Planning: The system utilizes FirstAssist AI™, an image recognition software that identifies critical anatomical structures using ultrasound, enabling personalized treatment plans tailored to each patient’s prostate anatomy.The system utilizes FirstAssist AI™, an image recognition software that identifies critical anatomical structures using ultrasound, enabling personalized treatment plans tailored to each patient’s prostate anatomy. Advanced Visualization: HYDROS™ combines advanced ultrasound imaging with digital cystoscopy, providing surgeons with a detailed, multi-dimensional view of the prostate for enhanced precision and surgical planning.HYDROS™ combines advanced ultrasound imaging with digital cystoscopy, providing surgeons with a detailed, multi-dimensional view of the prostate for enhanced precision and surgical planning. Robotic-Assisted Waterjet Resection: The system employs a robotic-assisted, heat-free waterjet to remove obstructive prostate tissue while preserving key anatomical structures, minimizing the risk of complications like incontinence or erectile dysfunction.The system employs a robotic-assisted, heat-free waterjet to remove obstructive prostate tissue while preserving key anatomical structures, minimizing the risk of complications like incontinence or erectile dysfunction. Streamlined Workflow: HYDROS™ features an integrated tower for efficient setup, an adjustable touchscreen for improved ergonomics, and user-friendly software to guide surgeons through the procedure.Early Success and Expanding AccessMount Sinai urologists have successfully performed the health system’s first three HYDROS™ procedures, with all patients responding well and being discharged the following day

The Robot Report
Jan 6th, 2025
Robotics Investments Top $7.4B In October 2024

Robotics investments topped $7.4 billion for the month of October 2024, the result of 77 funding rounds. The investment total was led by Waymo’s $5.6 billion raise, which is the largest single round of the year through November. October’s total was the largest through the first 10 months of the year. The previous monthly high was the $3.7 billion raised in September 2024. The total investment for the period of January through October 2024 was more than $20 billion. Developers of autonomous driving technologies once again dominated the list of largest investments for the month

Bizjournals
Oct 29th, 2024
Biotech firm announces $175M public stock offering

Procept BioRobotics announce a $175 million public stock offering, along with successful Q3 earnings.

MarketBeat
Aug 14th, 2024
Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?

PROCEPT BioRobotics operates in the medical sector and competes with medical robot and device makers like Intuitive Surgical, Medtronic PLC NYSE: MDT, and Zimmer Biomet Holdings NYSE: ZBH.